Uy Ear
Stock Analyst at Mizuho
(4.20)
# 528
Out of 5,091 analysts
76
Total ratings
50%
Success rate
18.51%
Average return
Main Sectors:
Stocks Rated by Uy Ear
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| QURE uniQure | Maintains: Outperform | $60 → $33 | $21.77 | +51.58% | 6 | Dec 9, 2025 | |
| EOLS Evolus | Maintains: Outperform | $20 → $19 | $6.97 | +172.60% | 4 | Dec 2, 2025 | |
| ACAD ACADIA Pharmaceuticals | Maintains: Neutral | $24 → $29 | $26.76 | +8.37% | 15 | Dec 2, 2025 | |
| ARQT Arcutis Biotherapeutics | Maintains: Outperform | $32 → $37 | $31.03 | +19.24% | 15 | Nov 28, 2025 | |
| RLMD Relmada Therapeutics | Upgrades: Outperform | $1 → $10 | $4.17 | +139.81% | 2 | Nov 19, 2025 | |
| SRPT Sarepta Therapeutics | Upgrades: Outperform | $19 → $26 | $21.86 | +18.94% | 9 | Nov 5, 2025 | |
| ALKS Alkermes | Maintains: Outperform | $40 → $45 | $29.41 | +53.01% | 6 | Oct 27, 2025 | |
| MBX MBX Biosciences | Maintains: Outperform | $38 → $56 | $31.39 | +78.40% | 2 | Sep 24, 2025 | |
| TECX Tectonic Therapeutic | Maintains: Outperform | $51 → $85 | $20.01 | +324.79% | 2 | May 15, 2025 | |
| RNAC Cartesian Therapeutics | Initiates: Buy | $40 | $6.72 | +495.24% | 1 | May 24, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $116 → $140 | $154.99 | -9.67% | 10 | Feb 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $36 → $40 | $201.62 | -80.16% | 1 | Jun 7, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $10 | $2.48 | +303.23% | 1 | Mar 17, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $5 → $3 | $1.20 | +150.00% | 2 | Mar 1, 2023 |
uniQure
Dec 9, 2025
Maintains: Outperform
Price Target: $60 → $33
Current: $21.77
Upside: +51.58%
Evolus
Dec 2, 2025
Maintains: Outperform
Price Target: $20 → $19
Current: $6.97
Upside: +172.60%
ACADIA Pharmaceuticals
Dec 2, 2025
Maintains: Neutral
Price Target: $24 → $29
Current: $26.76
Upside: +8.37%
Arcutis Biotherapeutics
Nov 28, 2025
Maintains: Outperform
Price Target: $32 → $37
Current: $31.03
Upside: +19.24%
Relmada Therapeutics
Nov 19, 2025
Upgrades: Outperform
Price Target: $1 → $10
Current: $4.17
Upside: +139.81%
Sarepta Therapeutics
Nov 5, 2025
Upgrades: Outperform
Price Target: $19 → $26
Current: $21.86
Upside: +18.94%
Alkermes
Oct 27, 2025
Maintains: Outperform
Price Target: $40 → $45
Current: $29.41
Upside: +53.01%
MBX Biosciences
Sep 24, 2025
Maintains: Outperform
Price Target: $38 → $56
Current: $31.39
Upside: +78.40%
Tectonic Therapeutic
May 15, 2025
Maintains: Outperform
Price Target: $51 → $85
Current: $20.01
Upside: +324.79%
Cartesian Therapeutics
May 24, 2024
Initiates: Buy
Price Target: $40
Current: $6.72
Upside: +495.24%
Feb 8, 2024
Maintains: Neutral
Price Target: $116 → $140
Current: $154.99
Upside: -9.67%
Jun 7, 2023
Maintains: Buy
Price Target: $36 → $40
Current: $201.62
Upside: -80.16%
Mar 17, 2023
Reiterates: Buy
Price Target: $10
Current: $2.48
Upside: +303.23%
Mar 1, 2023
Maintains: Buy
Price Target: $5 → $3
Current: $1.20
Upside: +150.00%